Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Warrant (NQ: NXLIW )

0.3600 +0.0900 (+33.33%)
Streaming Delayed Price Updated: 12:07 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nexalin Technology, Inc. - Warrant

< Previous 1 2 Next >
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients 
From Nexalin Technology, Inc.
Via GlobeNewswire
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients
Nexalin says the study published in the Journal of Alzheimer's Disease shows DIFS may enhance cognition in mild Alzheimer's patients. 
Via Benzinga
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
From Nexalin Technology, Inc.
Via GlobeNewswire
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study
Nexalin Technology's clinical trial results highlight notable cognitive improvements in Alzheimer's patients using Deep Intracranial Frequency Stimulation technology. The study showed significant... 
Via Benzinga
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial Frequency Stimulation (DIFS) technology for mental health treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Closing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders 
From Nexalin Technology, Inc.
Via GlobeNewswire
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
Via ACCESSWIRE
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
From Nexalin Technology, Inc.
Via GlobeNewswire
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
Previously served as Acting General Counsel to the Department of Veterans Affairs 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
Company’s International Reach Expanding with Latest Regulatory Approval 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Unveils Next-Generation HALO™ Clarity
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
Results published in General Psychiatry, a leading peer-reviewed journal 
From Nexalin Technology, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.